The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan
碩士 === 高雄醫學大學 === 藥學研究所碩士在職專班 === 94 === Background: Chronic hepatitis C virus (HCV) infection affects 170 million people worldwide. The prevalence of chronic hepatitis C is 2% to 5% in Taiwan, but 20-60% in some areas. The optimal therapeutic regimen for hepatitis C is pegylated interferon in combi...
Main Authors: | , |
---|---|
Other Authors: | |
Format: | Others |
Language: | zh-TW |
Published: |
2006
|
Online Access: | http://ndltd.ncl.edu.tw/handle/84910107206325271259 |
id |
ndltd-TW-094KMC05551038 |
---|---|
record_format |
oai_dc |
spelling |
ndltd-TW-094KMC055510382015-12-16T04:32:13Z http://ndltd.ncl.edu.tw/handle/84910107206325271259 The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan 台灣某三家區域教學醫院C型肝炎以peginterferonalfa2b與ribavirin合併治療結果分析 Wei-Hsin Ko 柯維信 碩士 高雄醫學大學 藥學研究所碩士在職專班 94 Background: Chronic hepatitis C virus (HCV) infection affects 170 million people worldwide. The prevalence of chronic hepatitis C is 2% to 5% in Taiwan, but 20-60% in some areas. The optimal therapeutic regimen for hepatitis C is pegylated interferon in combination with ribavirin. The duration of treatment may be individualized by the genotype. Patients with genotype 1 required treatment for 48 weeks and a standard dose of ribavirin; those with HCV genotype 2 or 3 seem to be adequately treated with a low dose of ribavirin. Objectives: The objectives of this study are to analyze the predictive factors of sustained response and the relationship medication dose and adverse reaction, so as to provide references of treatment. Methods: Data was collected from an outpatient computerized prescription data base of three regional hospitals from January 1, 2002, through December 31, 2005. Patients who were diagnosed as hepatitis C and were treated by combination of peginterferon alfa 2b and ribavirin were included. The data analysis includes the relationship between therapeutic response and genotype, age, stage of fibrosis; the relationship between abnormality of laboratory data and ribavirin dose and peginterferon alfa 2b dose. Statistical methods used in this study are chi-square test, independent-samples T test and paired T test. We used SPSS (statistical package for social science) 8.0 for Windows software to compile statistics. Results and conclusions: After six months finished treatment, 46 patients are of the sustained biochemical response (47.6 % for intention-to-treat, 60.6 % for per protocol). In total 91 treated patients, there are 66 patients with abnormal white blood cell count (75.0 %), 65 patients (73.9 %) with abnormal hemoglobulin, 27 patients (64.2 %) with abnormal absolute neutrophil count, 31 patients (47.7 %) with abnormal platelet count, 8 patients (10.8%) with abnormal total bilirubin, and 2 patients (2.5 %) with abnormal thyroid stimulating hormone. The response of treatment is related to age and the genotype of hepatitis C virus (P < 0.05), but not related to gender and weight (P > 0.05). We can not conclude if the occurrences of abnormal laboratory data are related to the dosage of peginterferon alfa 2b and ribavirin. 吳信昇 2006 學位論文 ; thesis 59 zh-TW |
collection |
NDLTD |
language |
zh-TW |
format |
Others
|
sources |
NDLTD |
description |
碩士 === 高雄醫學大學 === 藥學研究所碩士在職專班 === 94 === Background:
Chronic hepatitis C virus (HCV) infection affects 170 million people worldwide. The prevalence of chronic hepatitis C is 2% to 5% in Taiwan, but 20-60% in some areas. The optimal therapeutic regimen for hepatitis C is pegylated interferon in combination with ribavirin. The duration of treatment may be individualized by the genotype. Patients with genotype 1 required treatment for 48 weeks and a standard dose of ribavirin; those with HCV genotype 2 or 3 seem to be adequately treated with a low dose of ribavirin.
Objectives:
The objectives of this study are to analyze the predictive factors of sustained response and the relationship medication dose and adverse reaction, so as to provide references of treatment.
Methods:
Data was collected from an outpatient computerized prescription data base of three regional hospitals from January 1, 2002, through December 31, 2005. Patients who were diagnosed as hepatitis C and were treated by combination of peginterferon alfa 2b and ribavirin were included.
The data analysis includes the relationship between therapeutic response and genotype, age, stage of fibrosis; the relationship between abnormality of laboratory data and ribavirin dose and peginterferon alfa 2b dose.
Statistical methods used in this study are chi-square test, independent-samples T test and paired T test. We used SPSS (statistical package for social science) 8.0 for Windows software to compile statistics.
Results and conclusions:
After six months finished treatment, 46 patients are of the sustained biochemical response (47.6 % for intention-to-treat, 60.6 % for per protocol). In total 91 treated patients, there are 66 patients with abnormal white blood cell count (75.0 %), 65 patients (73.9 %) with abnormal hemoglobulin, 27 patients (64.2 %) with abnormal absolute neutrophil count, 31 patients (47.7 %) with abnormal platelet count, 8 patients (10.8%) with abnormal total bilirubin, and 2 patients (2.5 %) with abnormal thyroid stimulating hormone.
The response of treatment is related to age and the genotype of hepatitis C virus (P < 0.05), but not related to gender and weight (P > 0.05). We can not conclude if the occurrences of abnormal laboratory data are related to the dosage of peginterferon alfa 2b and ribavirin.
|
author2 |
吳信昇 |
author_facet |
吳信昇 Wei-Hsin Ko 柯維信 |
author |
Wei-Hsin Ko 柯維信 |
spellingShingle |
Wei-Hsin Ko 柯維信 The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan |
author_sort |
Wei-Hsin Ko |
title |
The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan |
title_short |
The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan |
title_full |
The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan |
title_fullStr |
The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan |
title_full_unstemmed |
The analysis of hepatitis C treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in Taiwan |
title_sort |
analysis of hepatitis c treatment with peginterferon alfa 2b and ribavirin in three regional hospitals in taiwan |
publishDate |
2006 |
url |
http://ndltd.ncl.edu.tw/handle/84910107206325271259 |
work_keys_str_mv |
AT weihsinko theanalysisofhepatitisctreatmentwithpeginterferonalfa2bandribavirininthreeregionalhospitalsintaiwan AT kēwéixìn theanalysisofhepatitisctreatmentwithpeginterferonalfa2bandribavirininthreeregionalhospitalsintaiwan AT weihsinko táiwānmǒusānjiāqūyùjiàoxuéyīyuàncxínggānyányǐpeginterferonalfa2byǔribavirinhébìngzhìliáojiéguǒfēnxī AT kēwéixìn táiwānmǒusānjiāqūyùjiàoxuéyīyuàncxínggānyányǐpeginterferonalfa2byǔribavirinhébìngzhìliáojiéguǒfēnxī AT weihsinko analysisofhepatitisctreatmentwithpeginterferonalfa2bandribavirininthreeregionalhospitalsintaiwan AT kēwéixìn analysisofhepatitisctreatmentwithpeginterferonalfa2bandribavirininthreeregionalhospitalsintaiwan |
_version_ |
1718149389078233088 |